227 related articles for article (PubMed ID: 35666871)
1. Rituximab abrogates aquaporin-4-specific germinal center activity in patients with neuromyelitis optica spectrum disorders.
Damato V; Theorell J; Al-Diwani A; Kienzler AK; Makuch M; Sun B; Handel A; Akdeniz D; Berretta A; Ramanathan S; Fower A; Whittam D; Gibbons E; McGlashan N; Green E; Huda S; Woodhall M; Palace J; Sheerin F; Waters P; Leite MI; Jacob A; Irani SR
Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2121804119. PubMed ID: 35666871
[TBL] [Abstract][Full Text] [Related]
2. Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder.
Kunchok A; Malpas C; Nytrova P; Havrdova EK; Alroughani R; Terzi M; Yamout B; Hor JY; Karabudak R; Boz C; Ozakbas S; Olascoaga J; Simo M; Granella F; Patti F; McCombe P; Csepany T; Singhal B; Bergamaschi R; Fragoso Y; Al-Harbi T; Turkoglu R; Lechner-Scott J; Laureys G; Oreja-Guevara C; Pucci E; Sola P; Ferraro D; Altintas A; Soysal A; Vucic S; Grand'Maison F; Izquierdo G; Eichau S; Lugaresi A; Onofrj M; Trojano M; Marriott M; Butzkueven H; Kister I; Kalincik T
Mult Scler Relat Disord; 2020 Feb; 38():101868. PubMed ID: 31877445
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
Tahara M; Oeda T; Okada K; Kiriyama T; Ochi K; Maruyama H; Fukaura H; Nomura K; Shimizu Y; Mori M; Nakashima I; Misu T; Umemura A; Yamamoto K; Sawada H
Lancet Neurol; 2020 Apr; 19(4):298-306. PubMed ID: 32199095
[TBL] [Abstract][Full Text] [Related]
4. Orbital Ectopic Lymphoid Follicles with Germinal Centers in Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorders.
Chan KH; Lee R; Lau KK; Loong F
Front Immunol; 2017; 8():1947. PubMed ID: 29387055
[TBL] [Abstract][Full Text] [Related]
5. Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production.
Cotzomi E; Stathopoulos P; Lee CS; Ritchie AM; Soltys JN; Delmotte FR; Oe T; Sng J; Jiang R; Ma AK; Vander Heiden JA; Kleinstein SH; Levy M; Bennett JL; Meffre E; O'Connor KC
Brain; 2019 Jun; 142(6):1598-1615. PubMed ID: 31056665
[TBL] [Abstract][Full Text] [Related]
6. Effect of rituximab on disease activity in latin American patients with anti-aquaporin-4 (+) neuromyelitis optica spectrum disorder.
Gomez-Figueroa E; Noriega-Morales G; Casallas-Vanegas A; Zabala-Angeles I; Garcia-Estrada C; Neri D; Sarachaga AJ; Rivas-Alonso V; Corona-Vazquez T; Flores-Rivera J
Clin Neurol Neurosurg; 2020 Sep; 196():106007. PubMed ID: 32559706
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis.
Damato V; Evoli A; Iorio R
JAMA Neurol; 2016 Nov; 73(11):1342-1348. PubMed ID: 27668357
[TBL] [Abstract][Full Text] [Related]
8. Anti-aquaporin-4 immune complex stimulates complement-dependent Th17 cytokine release in neuromyelitis optica spectrum disorders.
Nishiyama S; Seok JM; Wright AE; Lotan I; Mikami T; Drosu NC; Bobrowski-Khoury N; Anderson MR; Bilodeau PA; Schindler P; Paul F; Aoki M; Yeaman MR; Levy M;
Sci Rep; 2024 Feb; 14(1):3146. PubMed ID: 38326464
[TBL] [Abstract][Full Text] [Related]
9. Rituximab-induced interstitial lung disease in a patient with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder.
Ahn SH; Kim SM; Sung JJ
Mult Scler Relat Disord; 2018 Feb; 20():192-193. PubMed ID: 29414297
[TBL] [Abstract][Full Text] [Related]
10. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
Carnero Contentti E; Correale J
J Neuroinflammation; 2021 Sep; 18(1):208. PubMed ID: 34530847
[TBL] [Abstract][Full Text] [Related]
11. Impact of rituximab treatment regime on time to relapse in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
Nasir M; Hone L; Tallantyre E; Kelly P; Leite MI; Robertson N; Bestwick J; Huda S; Palace J; Dobson R
Mult Scler Relat Disord; 2024 May; 85():105528. PubMed ID: 38479046
[TBL] [Abstract][Full Text] [Related]
12. Aquaporin-4 in Neuromyelitis Optica Spectrum Disorders: A Target of Autoimmunity in the Central Nervous System.
Abe Y; Yasui M
Biomolecules; 2022 Apr; 12(4):. PubMed ID: 35454180
[TBL] [Abstract][Full Text] [Related]
13. Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder.
Kim SH; Hyun JW; Kim HJ
Neurochem Int; 2019 Nov; 130():104347. PubMed ID: 30513364
[TBL] [Abstract][Full Text] [Related]
14. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial.
Palace J; Wingerchuk DM; Fujihara K; Berthele A; Oreja-Guevara C; Kim HJ; Nakashima I; Levy M; Terzi M; Totolyan N; Viswanathan S; Wang KC; Pace A; Yountz M; Miller L; Armstrong R; Pittock S;
Mult Scler Relat Disord; 2021 Jan; 47():102641. PubMed ID: 33310418
[TBL] [Abstract][Full Text] [Related]
15. Memantine ameliorates motor impairments and pathologies in a mouse model of neuromyelitis optica spectrum disorders.
Yick LW; Tang CH; Ma OK; Kwan JS; Chan KH
J Neuroinflammation; 2020 Aug; 17(1):236. PubMed ID: 32782018
[TBL] [Abstract][Full Text] [Related]
16. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG
J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the binding pattern of human aquaporin-4 autoantibodies in patients with neuromyelitis optica spectrum disorders.
Tuller F; Holzer H; Schanda K; Aboulenein-Djamshidian F; Höftberger R; Khalil M; Seifert-Held T; Leutmezer F; Berger T; Reindl M
J Neuroinflammation; 2016 Jul; 13(1):176. PubMed ID: 27371173
[TBL] [Abstract][Full Text] [Related]
18. Dynamics of AQP4 upon exposure to seropositive patient serum before and after Rituximab therapy in Neuromyelitis Optica: A cell-based study.
Saha S; Mukherjee S; Guha G; Mukhopadhyay D
J Neuroimmunol; 2021 Dec; 361():577752. PubMed ID: 34715591
[TBL] [Abstract][Full Text] [Related]
19. Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica.
Wilson R; Makuch M; Kienzler AK; Varley J; Taylor J; Woodhall M; Palace J; Leite MI; Waters P; Irani SR
Brain; 2018 Apr; 141(4):1063-1074. PubMed ID: 29447335
[TBL] [Abstract][Full Text] [Related]
20. [Actual issues of serum aquaporin-4 autoantibodies evaluation in the diagnostics of neuromyelitis optica spectrum disorders].
Krasnov VS; Totolyan NA; Nazarov VD; Mazing AV; Makshakov GS; Lapin SV; Evdoshenko EP; Skoromets AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(7. Vyp. 2):24-31. PubMed ID: 32844626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
